Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
tsinakaltseedi mõju teistele ravimitele
effect of cinacalcet on other medications
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsinakaltseedi farmakokineetika ei muutu ajaga.
the pharmacokinetics of cinacalcet does not change over time.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
vajalik võib olla tsinakaltseedi annuse reguleerimine.
dose adjustment of cinacalcet may be required.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tsinakaltseedi annuse vähendamine või manustamise katkestamine
reduce or withhold dose of cinacalcet.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
maksatalitlus ei mõjuta tsinakaltseedi seondumist valkudega.
protein binding of cinacalcet is not affected by impaired hepatic function.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
pth taseme langus on korrelatsioonis tsinakaltseedi kontsentratsiooniga.
reductions in pth levels correlate with cinacalcet concentration.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
kerge maksakahjustus ei mõjutanud tsinakaltseedi farmakokineetikat märkimisväärselt.
mild hepatic impairment did not notably affect the pharmacokinetics of cinacalcet.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
kliinilisi andmeid tsinakaltseedi manustamise kohta rasedatele ei ole.
there are no clinical data from the use of cinacalcet in pregnant women.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tsinakaltseedi kliinilistes uuringutes mõõdeti pth taset manustamisintervalli lõpus.
pth levels in cinacalcet clinical trials were measured at the end of the dosing interval.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
sugu: tsinakaltseedi kliirens võib naistel olla madalam kui meestel.
gender: clearance of cinacalcet may be lower in women than in men.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
maksapuudulikkus: kerge maksakahjustus ei mõjutanud tsinakaltseedi farmakokineetikat märkimisväärselt.
hepatic insufficiency: mild hepatic impairment did not notably affect the pharmacokinetics of cinacalcet.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
toiduga koos võetuna suureneb tsinakaltseedi biosaadavus ligikaudu 50%…80%.
administration of mimpara with food results in an approximate 50 – 80% increase in cinacalcet bioavailability.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsinakaltseedi turuletulekujärgse kasutamise käigus on täheldatud ülitundlikkusreaktsioone, sh angioödeemi ja urtikaariat.
hypersensitivity reactions including angioedema and urticaria have been identified during post- marketing use of cinacalcet.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
info tsinakaltseedi farmakokineetilise/farmakodünaamilise profiili kohta on esitatud lõigus 5.1.
information regarding the pharmacokinetic/pharmacodynamic (pk/pd) profile of cinacalcet is given in section 5.1
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsinakaltseedi annus varieerus vahemikus 30 mg kaks korda päevas kuni 90 mg neli korda päevas.
cinacalcet was administered at doses ranging from 30 mg twice daily to 90 mg four times daily.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
lapsed ja noorukid: tsinakaltseedi farmakokineetikat alla 18 aasta vanustel patsientidel ei ole uuritud.
children and adolescents: the pharmacokinetics of cinacalcet have not been studied in patients < 18 years of age.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
tsinakaltseedi kliirens on suitsetajatel kõrgem kui mittesuitsetajatel tõenäoliselt cyp1a2 vahendusel toimuva metabolismi induktsiooni tõttu.
clearance of cinacalcet is higher in smokers than in non-smokers, likely due to induction of cyp1a2- mediated metabolism.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
cyp1a2 inhibiitorite (nt fluvoksamiin, tsiprofloksatsiin) mõju tsinakaltseedi kontsentratsioonile vereplasmas ei ole uuritud.
the effect of cyp1a2 inhibitors (e.g. fluvoxamine, ciprofloxacin) on cinacalcet plasma levels has not been studied.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
sevelameer: koosmanustamine sevelameeriga (2400 mg kolm korda päevas) ei mõjutanud tsinakaltseedi farmakokineetikat.
sevelamer: co-administration of sevelamer (2400 mg, three times a day) did not affect the pharmacokinetics of cinacalcet.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tsinakaltseedi keskmine poolväärtusaeg pikenes mõõduka raskusastmega maksakahjustusega patsientidel 33% ja raskekujulise maksakahjustusega patsientidel 70%.
the mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: